Journal profile · PHARMACOLOGY & PHARMACY
Drug Target Insights
ISSN 1177-3928 · AboutScience Srl · Italy
Drug Target Insights: CAS Zone 4 · Medicine (2025 upgraded edition); fully open access; APC charged, amount not published; median 106 days to acceptance (16 articles, last 24 months); 11 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Drug Target Insights is published by AboutScience Srl and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Antibiotic Resistance in Bacteria, Pharmacological Effects of Natural Compounds and Gastrointestinal motility and disorders, together about 20.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Drug Target Insights (DTI) is an international, indexed, peer-reviewed, open access, online only journal, published once a year. It covers current developments in all areas of the field of clinical therapeutics, focusing on molecular drug targets which include disease-specific proteins, receptors, enzymes, and genes. The journal aims to explore the impact of new therapeutic agents on patient acceptability, preference, satisfaction and quality of life and welcomes research on the molecular mechanisms of drug action, including the elucidation of biochemical and cellular pathways that underlie therapeutic effects and mechanistic studies spanning oncology, infectious diseases, metabolic disorders, and related fields. It further addresses clinical therapeutics and real‑world applications, featuring clinical trial data, case reports, and observational studies that evaluate the effectiveness and safety of novel therapies, alongside investigations into patient‑centered outcomes and quality‑of‑life measures
From the journal's Aims & Scope
Research area (LetPub): PHARMACOLOGY & PHARMACY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology7.8%
- Pharmacological Effects of Natural CompoundsPharmacology, Toxicology and Pharmaceutics7%
- Gastrointestinal motility and disordersMedicine5.5%
- Computational Drug Discovery MethodsComputer Science4.7%
- Diabetes Treatment and ManagementMedicine4.7%
- Antibiotic Use and ResistanceImmunology and Microbiology4.7%
- Nanoparticle-Based Drug DeliveryMaterials Science3.9%
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 4.7LetPub ·
- SJR 2026-06
- 0.69LetPub ·
- SNIP 2026-06
- 0.74LetPub ·
- h-index
- 27OpenAlex ·
- i10-index
- 72OpenAlex ·
- 2-year mean citedness
- 3.9OpenAlex ·
- Self-citation rate
- 2.7%LetPub ·
- Share of gold OA articles
- 94.44%LetPub ·
Volume
- Articles per year
- 11LetPub ·
Articles by year OpenAlex count · 243 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 6 | 6 | 2 |
| 2025 | 11 | 11 | 32 |
| 2024 | 14 | 14 | 87 |
| 2023 | 16 | 16 | 179 |
| 2022 | 13 | 13 | 113 |
| 2021 | 5 | 5 | 131 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
106 daysMedian, submission to acceptance · P25–P75 78 days – 132 days
- Acceptance to online
- median 26 days (16 articles)
- Submission to online
- median 130 days
- Sample
- 16 articles with submission and acceptance dates (20 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 8 weeksLetPub ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 1,500 | No | CC BY-NC | |
| OpenAlex | EUR 1,500 | — | — | |
| LetPub | EUR 1,500 | No | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- ≤ 250 words
- Reference style
- AMA
- Suggested reviewers
- Optional
- Highlights
- Optional
- Graphical abstract
- Optional
- Cover letter
- Optional
- Not considered
- preprint; conference paper; other
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access
Open access under CC-BY-NC 4.0 license; unlimited reader access with no embargo period. Model summary
Authors contributing to Drug Target Insights agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.
Source ↗Publisher website ·- Peer review
Content archived in Portico for permanent preservation. Model summary
All of this journal content is archived in Portico, which provides permanent archiving for electronic scholarly journals.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- AboutScience Srl
- Country or region
- Italy
- Language
- English
- ISSN
- 1177-3928
- Official links
- Journal homepage ↗OpenAlex
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Drug Target Insights
What CAS zone is Drug Target Insights in?
In the 2025 upgraded edition of the CAS Journal Ranking, Drug Target Insights is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Drug Target Insights?
Based on the dates recorded on 16 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 106 days (interquartile range 78–132 days); authors report an average review time of about 8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Drug Target Insights?
According to the journal's author guidelines: Abstract: ≤ 250 words; Reference style: AMA; Suggested reviewers: Optional; Highlights: Optional; Graphical abstract: Optional; Cover letter: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Drug Target Insights?
According to LetPub and DOAJ records, Drug Target Insights is indexed in ESCI, Scopus and DOAJ.
Is Drug Target Insights open access, and what is the APC?
Drug Target Insights is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .